AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03447691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Des (volatile anesthetic-desflurane)
Description: Inducing unconciouness with 1.5 to 2 mg/kg of propofol, Intubation is performed 3 minutes after administration of remifentanil 1-2 mcg / kg and rocuronium 0.6 mg / kg. Desflurane concentration is maintained 3-7% (0.7-1.1 MAC) and remifentanil continuous infusion (0.02-0.2 mcg / kg / min).
Study NCT03447691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA (Total intravenous anesthesia with propofol and remifentanil)
Description: TIVA group is administered with intravenous anesthetic using commercial target controlled infusion (TCI) pump. Anesthesia is induced and maintained with 2-6 mcg / ml propofol and 2-6 ng / ml remifentanil, which are converted to the effect site concentration. After administrating rocuronium 0.6mg/kg, intubation is performed.
Study NCT03800693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT03800693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Given IV
Study NCT04571073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model
Description: Using physical exam and manual manipulation skills informed by the FDM, he identified and treated locations of presumed fascial distortion about the plantar area of the foot; distortions could include any of the six reported fascial anomalies in the FDM: continuum distortions, trigger bands, herniated trigger points, folding distortions, cylinder distortions, and tectonic fixations. Each distortion is associated with a recommended reparative manipulation. The purported mechanism of action is that the distortion-specific manipulation restores normal fascial homogeneity.
Study NCT03800693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT03800693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT03800693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT04723654 — intervention group
Intervention type: DEVICE
Intervention: Wireless Wearable Vital Sign Monitor
Description: Placement of wireless wearable vital sign monitors on patients limbs for up to 48 hours
Study NCT02839278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT00681018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid human milk fortifier
Description: Liquid human milk fortifier added to human milk
Study NCT00681018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Powder human milk fortifier
Description: Powder human milk fortifier added to human milk
Study NCT04457115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: Thoracic paravertebral block performed at T2-T3 and T4-T5 levels with administration of Ropivacaine 0.7% 8 ml for each level
Study NCT04457115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane Block
Description: Erector spinae plane block performed at T2 and T5 levels with administration of Ropivacaine 0.5% 12 ml for each level
Study NCT02298387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-305B83
Description: intravenous (in the vein) infusions
Study NCT04521608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention- Home-based Pulmonary Rehabilitation
Description: Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
Study NCT03707431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT
Description: The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
Study NCT03707431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Education
Description: The pain education website provides publicly available educational information about pancreatitis and abdominal pain. There is general information about pancreatitis from available web sources (e.g., National Pancreas Foundation) as well as information about chronic pain in childhood. The content does not include any instruction in the behavioral and cognitive skills taught within the WebMAP program.
Study NCT03833167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg
Description: Administered by IV infusion on Day 1 of each 42-day cycle
Study NCT03833167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion on Day 1 of each 42-day cycle
Study NCT01923818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: orally active direct factor Xa inhibitor
Study NCT01180166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: 200 milligram (mg) of nimotuzumab per week during radiation period
Study NCT00546468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy assisted distal gastrectomy
Description: under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
Study NCT00546468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open distal gastrectomy
Description: Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
Study NCT02594241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl-Prednisolone
Description: Single-shot 125 mg infusion given immediately after induction of anesthesia.
Study NCT02594241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
Study NCT03895021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pisando Fuerte
Description: Pisando Fuerte, a linguistically and culturally appropriate version for Spanish speakers of an evidence-based fall prevention program (Stepping On \[SO\]).
Study NCT01923818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: non-steroidal anti-inflammatory drugs
Study NCT01923818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT01923818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT00004136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Tumors heated to target temperature by electrodes for maximum of 20 minutes
Study NCT01112462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg/Phenylephrine 5 mg tablets
Description: 2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period
Study NCT01112462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 1000 mg/Phenylephrine 10 mg sachet
Description: 1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period
Study NCT00758758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Hedrocel
Study NCT00758758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Allograft
Study NCT00758758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Autograft
Study NCT00083772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
Study NCT04733313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guıded quadratus lumborum block
Description: Administering local aneshtetic agent with a block needle using the in-plane technique, bilaterally. Lumbar interfascial triangle, where the middle lumbar fascia joins the deep lamina of the posterior layer on the lateral border of the erector spinae was targeted as the optimal point of injection.
Study NCT03089619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human-Spongiosa
Description: after tooth extraction, the dental alveolus is filled with the bone substitute material (Human-Spongiosa) and covered with a membrane (mucoderm®)
Study NCT03089619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: collacone®
Description: after tooth extraction, the dental alveolus is filled with the bone substitute material (collacone®) and covered with a membrane (mucoderm®)
Study NCT02856529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.
Study NCT02856529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General session
Description: A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
Study NCT04402671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-cross-linked porcine skin collagen membrane
Description: non-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland.
Study NCT04402671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glutaraldehyde cross-linked bovine collagen membrane
Description: glutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA.
Study NCT00710164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)
Description: 14 days of XSCR capsule
Study NCT00710164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 days of Placebo
Study NCT03049111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Der f
Description: Inhalation of Der f in mild asthmatics who are sensitive to Der f.
Study NCT02333773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
Study NCT04859686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Treatment
Description: Participants received two treatments per week over eight weeks, 35-40 minutes each.~At each treatment, participants were treated with 10 body and two ear points: seven major points on either the front or back of the body. The treatment position alternated between sessions, such that the first session was on the back, with the next session on the front, unless a physical limitation prevented alternation.
Study NCT02546635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-024.HCl
Description: AX-024.HCl will be administered as per the protocol defined frequency and dose level
Study NCT04508140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Biopsy
Description: In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.
Study NCT04508140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BO-112 with pembrolizumab
Description: BO-112 was administered in the liver metastasis at the dose of 1mg (1.2 mL) in combination with intravenous pembrolizumab given at the fixed dose of 200 mg, every 3 weeks for up to 35 cycles (2 years). During the first cycle, BO-112 was administered on D1 and D8.
Study NCT00554112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise
Study NCT01284530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPM XR
Description: Equivalent TDD in XR form, QD, Day 1-14
Study NCT02747654 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genotype
Description: Patients were randomly assigned to a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight) or model-based treatment group; INH dose determined based on developed model,
Study NCT00068783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00068783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02162849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline Dosing: 0.5 mg/day by mouth for Days 1-3; 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter.
Study NCT02162849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11 weeks.
Study NCT02162849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
Study NCT02162849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
Study NCT02162849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. Questionnaires should take about 30-45 minutes total to complete. On Days 17, 24, 38, and 73, done over the phone.
Study NCT02162849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Sessions
Description: Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. These sessions take about 15 minutes each time.
Study NCT02162849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lab Session
Description: Participant asked to watch slides. During the lab session, brain electrical activity checked with an electroencephalogram (EEG). Participant completes computer tasks, including questionnaires, that will measure emotions and attention level. These tasks should take about 90 minutes to complete. The lab session may last up to 2 hours.
Study NCT02162849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Test
Description: Saliva tested to check cotinine level at baseline, on Days 8 and 17, end of treatment visit, and at 3 months and 6 months after quitting smoking.
Study NCT01456390 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: iStent and iStent supra
Description: Implantation of two iStent devices and one iStent supra device
Study NCT03686826 — intervention group
Intervention type: PROCEDURE
Intervention: Acquisition of MEP und SSEP
Description: Acquisition of MEP und SSEP at two different time points within 1 to 30 days
Study NCT01016704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
Study NCT04148833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE-Paclitaxel
Description: LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks
Study NCT04148833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LDE-Placebo
Description: LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
Study NCT03029130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter extension
Description: Foley transurethral catheter placed to allow continuous drainage of urine.
Study NCT02810340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted MCV-5
Description: Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM), and 125 μg Al3+adjuvant.
Study NCT02810340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-Adjuvanted MCV-5
Description: Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, and 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM).
Study NCT02810340 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra®
Description: Menactra® vaccine was a clear to slightly turbid solution supplied in a 0.5 mL single dose vial. Each 0.5 mL dose of vaccine was formulated in sodium phosphate buffered isotonic sodium chloride solution to contain four mcg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 μg of diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 μg (0.000532%), by calculation.
Study NCT02528266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve Capping Device
Study NCT03004157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiopulmonary resuscitation
Description: CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
Study NCT00464386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: measure glucose levels on burn patients
Study NCT00052520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Given IV
Study NCT00052520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT00052520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo transplantation
Study NCT00974766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
Study NCT00052520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo transplantation
Study NCT00052520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00052520 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT00052520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies
Study NCT00052520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00052520 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT00052520 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies
Study NCT00052520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: staining method
Description: Correlative studies
Study NCT03117205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of Kinesio Taping®
Description: The technique was applied following the methods described in the original method for patellofemoral instability
Study NCT03117205 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio Taping® placebo application
Description: Simulation of the application of the Kinesio Taping® technique.
Study NCT03700398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: first OE
Description: optical enhancement(OE)，a kind of electron straining endoscopy
Study NCT03700398 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: first WLI
Description: the routine in the clinical practice